<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Neurology/Cerebrovascular%20Disease/Subarachnoid%20Hemorrhage/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Types - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Types", url: "#_top", children: [
          ]},
          {title: "Background", url: "#background", children: [
              {title: "Risk Factors", url: "#risk-factors" },
              {title: "Prevention of aSAH", url: "#prevention-of-asah" },
              {title: "Natural History of aSAH", url: "#natural-history-of-asah" },
          ]},
          {title: "Clinical Manifestations and Diagnosis of aSAH", url: "#clinical-manifestations-and-diagnosis-of-asah", children: [
              {title: "Diagnosis", url: "#diagnosis" },
          ]},
          {title: "Acute Management", url: "#acute-management", children: [
              {title: "Rebleeding Prevention", url: "#rebleeding-prevention" },
              {title: "Surgical/Endovascular Treatment", url: "#surgicalendovascular-treatment" },
              {title: "Cerebral Vasospasm and Delayed Cerebral Ischemia (DCI)", url: "#cerebral-vasospasm-and-delayed-cerebral-ischemia-dci" },
              {title: "Hydrocephalus secondary to aSAH", url: "#hydrocephalus-secondary-to-asah" },
              {title: "Seizures secondary to aSAH", url: "#seizures-secondary-to-asah" },
              {title: "Medical complications of aSAH", url: "#medical-complications-of-asah" },
          ]},
          {title: "Long-Term Management", url: "#long-term-management", children: [
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../../Neurocognitive%20and%20Degenerative%20Disorders/Dementia/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../../Neurocognitive%20and%20Degenerative%20Disorders/Dementia/" class="btn btn-xs btn-link">
        Dementia
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Intracranial%20Atherosclerotic%20Disease%20%28ICAD%29/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Intracranial%20Atherosclerotic%20Disease%20%28ICAD%29/" class="btn btn-xs btn-link">
        Intracranial Atherosclerotic Disease (ICAD)
      </a>
    </div>
    
  </div>

    

    <h1 id="types">Types</h1>
<ol>
<li>Aneurysmal (aSAH)</li>
<li><a href="../../../Critical%20Care/Neuro%20Critical%20Care/Traumatic%20Brain%20Injury/#Traumatic%20SAH">Traumatic SAH</a></li>
</ol>
<h1 id="background">Background</h1>
<h2 id="risk-factors">Risk Factors</h2>
<ul>
<li>Modifiable<ul>
<li>hypertension</li>
<li>smoking</li>
<li>alcohol abuse</li>
<li>sympathomimetic drug use</li>
</ul>
</li>
<li>Non-modifiable<ul>
<li>presence of unruptured cerebral aneurysm<ul>
<li>size &gt; 7 mm</li>
</ul>
</li>
<li>femal sex</li>
<li>history of previous aSAH</li>
<li>familial aneurym history</li>
<li>genetic syndromes (<a href="../../../Nephrology/Causes%20of%20Renal%20Failure/Polycystic%20Kidney%20Disease%20%28PKD%29/">ADPKD</a>, EDS-4)</li>
</ul>
</li>
</ul>
<h2 id="prevention-of-asah">Prevention of aSAH</h2>
<ol>
<li>Control hypertension</li>
<li>Reduce tobacco and alcohol use</li>
<li>Healthy diet</li>
<li>consider noninvasive screening to patients with familial aSAH or history of aSAH to evaluate for de novo aneurysms</li>
<li>After any aneurysm repair, immediate cerebrovascular imaging is generally recommended to identify remnants or recurrence of the aneurysm that may require treatment</li>
</ol>
<h2 id="natural-history-of-asah">Natural History of aSAH</h2>
<ul>
<li>median mortality is variable in studies</li>
<li>functional outcomes: Rates of persistent dependence of between 8% and 20% have been reported when the modified Rankin Scale is used</li>
<li>risk of early aneurysm rebleeding is high, and rebleeding is associated with very poor outcomes</li>
</ul>
<h1 id="clinical-manifestations-and-diagnosis-of-asah">Clinical Manifestations and Diagnosis of aSAH</h1>
<ul>
<li>classic "thunderclap headache" in 80% of awake patients, and 10-43% of patients have a preceding sentinel headache 2-8 weeks prior (this increases the risk of re-bleeding by 10x)</li>
<li>most patients are doing their normal daily activities as opposed to strenous physical activity</li>
<li>can be associated with initial N/V, stiff neck, photophobia, LOC, focal neurologic deficits. Up to 12% of patients die prior to medical attention.</li>
<li>Seizures can occur in 20% of patients after aSAH, most commonly in the first 24 hours</li>
</ul>
<h2 id="diagnosis">Diagnosis</h2>
<ol>
<li><em>Non-con CT head</em> is the cornerstone of diagnosis<ol>
<li>~100% sensitivity in the first 3 days</li>
<li>sensitivity decreases sharply after 5-7 days, and <em>lumbar puncture</em> is often then required to show xanthochromia</li>
</ol>
</li>
<li><em>CT angiography</em> can miss aneurysms &lt;3 mm in size</li>
<li>If CT is non-diagnostic, consider MRI or DSA (if planning NSX)</li>
</ol>
<h1 id="acute-management">Acute Management</h1>
<h2 id="rebleeding-prevention">Rebleeding Prevention</h2>
<p>Rebleeding is associated with very high mortality and a poor neurological prognosis. The risk is maximal in the first 2-12 hours, and up to 13% in the first 24 hours. More than 1/3 of rebleeds occur in the first 3 hours from symptom onset.
1. Blood pressure management
    1. <em>The optimal BP target is not known.</em> For most patients, the goal should be SBP &lt; 160 mmHg or MAP &lt; 110 mmHg (Class IIa)
3. Antifibrinolysis: patients with an unavoidable delay in obliteration of aneurysm, a significant risk of rebleeding, and no compelling medical contraindications, short-term (&lt;72 hours) therapy with <a href="../../../Critical%20Care/Transfusions%20and%20Bleeding/Tranexamic%20Acid/">tranexamic acid</a> or aminocaproic acid is reasonable to reduce the risk of early aneurysm rebleeding (Class IIa)</p>
<h2 id="surgicalendovascular-treatment">Surgical/Endovascular Treatment</h2>
<h2 id="cerebral-vasospasm-and-delayed-cerebral-ischemia-dci">Cerebral Vasospasm and Delayed Cerebral Ischemia (DCI)</h2>
<p>Narrowing (vasospasm) of the angiographically visible cerebral arteries after aSAH is common, occurring most frequently 7 to 10 days after aneurysm rupture and resolving spontaneously after 21 days. Radiographic vasospasm does NOT correlate well with symptomatic cerebral ischemia. DCI remains a large cause of death and disability after aSAH as well.</p>
<p>Management:
1.  <em>Nimodipine should be given to ALL patients with aSAH</em> (this improves neurological outcomes but not cerebral vasospasm). Whether other CCBs are useful is unknown
2. Maintain euvolemia and normal circulating blood volume
3. For patients with DCI, consider induced hypertension if tolerable 
4. For symptomatic vasospasm, consider cerebral angioplasty and/or selective intra-arterial vasodilatory therapy.
5. For monitoring and diagnosis, consider TCD, perfusion imaging with CT or MR</p>
<h2 id="hydrocephalus-secondary-to-asah">Hydrocephalus secondary to aSAH</h2>
<ol>
<li>CSF diversion --&gt; EVD or lumbar drainage</li>
</ol>
<h2 id="seizures-secondary-to-asah">Seizures secondary to aSAH</h2>
<ol>
<li>consider prophylactic AEDs in the immediate post-hemorrhagic poeriod</li>
<li>Routine long-term use of AEDs is not recommended, but can be considereed for patients with known risk factors for delayed epilepsy (prior seizure, hematoma, intractable hypertension, infarction, MCA aneurysm)</li>
</ol>
<h2 id="medical-complications-of-asah">Medical complications of aSAH</h2>
<ol>
<li>Sodium disorders<ol>
<li>Cerebral salt wasting/SIADH</li>
</ol>
</li>
<li>Fever --&gt; target normothermia</li>
<li>Dysglycemia -- target normal levels, avoid hypoglycemia </li>
</ol>
<h1 id="long-term-management">Long-Term Management</h1>
<h1 id="references">References</h1>
<ol>
<li>AHA/American Stroke Association aSAH 2012 Guidelines: <a href="https://www.ahajournals.org/doi/10.1161/str.0b013e3182587839">Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage | Stroke</a></li>
<li><a href="https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.119.025997">Treatment of Spontaneous Subarachnoid Hemorrhage | Stroke</a></li>
<li><a href="https://www.uptodate.com/contents/aneurysmal-subarachnoid-hemorrhage-treatment-and-prognosis">Aneurysmal subarachnoid hemorrhage: Treatment and prognosis - UpToDate</a></li>
<li>https://emcrit.org/ibcc/tbi/</li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../../Neurocognitive%20and%20Degenerative%20Disorders/Dementia/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../../Neurocognitive%20and%20Degenerative%20Disorders/Dementia/" class="btn btn-xs btn-link">
        Dementia
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Intracranial%20Atherosclerotic%20Disease%20%28ICAD%29/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Intracranial%20Atherosclerotic%20Disease%20%28ICAD%29/" class="btn btn-xs btn-link">
        Intracranial Atherosclerotic Disease (ICAD)
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>